“Emirates Drug” agrees to the first oral treatment of its kind globally for immunosuppressive disorder

The Emirates Drug Corporation has announced the adoption of the drug “Rilzbrotinib (Rilzabrutinib) The first oral inhibitors of the Tyrusin Kinaz proton for the treatment of immunodeficiency disease (ITP)It is a rare immune disorder that affects between 2 to 5 individuals in every 100,000 people around the world, and this achievement is a global precedence that reflects the UAE’s leadership in accelerating the availability of innovative treatments and meeting the medical needs of patients.

The adoption of this drug acquires exceptional importance, as it gives immune thrillers in the UAE and the region an early opportunity to benefit from an innovative treatment that contributes to accelerating their therapeutic path and achieving tangible improvement in the quality of their lives. This step comes within the framework of the state’s firm commitment to attracting and providing highly efficient advanced treatments, in line with the finest standards and international therapeutic protocols..

A new approach to treatment

The “Snovi” company developed by “Snovi” is a new treatment approach in restoring the balance of the work of the immune system and reaching the cause behind this disease.

By achieving this and increasing the number of platelets, the drug treats all of the symptoms and root causes of the disease. Clinical experiments showed promising results, as patients witnessed a great improvement in their health condition.

Innovative treatments

The Director General of the Emirates Drug Foundation, Dr. Fatima Al -Kaabi, stressed that this accreditation reflects the state’s commitment to providing the latest global treatments, and enhances its position as a leading destination in accelerating the availability of innovative medicines, as this achievement comes within the Foundation’s strategy to promote pharmaceutical security, adopting advanced treatment protocols, facilitating organizational procedures in cooperation with international partners.

She pointed out that this achievement confirms the success of the UAE’s pre -emptive policies in developing a flexible organizational environment that supports innovation and facilitates patients’ access to advanced treatments. The Emirates Drug Corporation continues its efforts to accelerate organizational procedures and enhance international cooperation, in order to establish the UAE’s position as a regional center for pharmaceutical innovation.

She added: “The adoption of the drug” Rilzbrotinib “reflects the commitment of the Emirates Drug Corporation to accelerate the availability of innovative treatments that create a real difference in the lives of patients, especially in the areas of rare and chronic diseases, and we are keen in the institution to adopt a pre -emptive approach based on innovation and global partnerships, in a way that ensures the provision of effective and safe treatment options according to the highest international standards, and enhances the readiness of the health system in the country to keep up with Fasting scientific developments.

In this context, the Director General of Specialized Care in “Sanofi” and the Gulf states, Pretty Votation, said: “We are proud of fruitful cooperation with the Emirates Drug Corporation to provide this innovative treatment for patients who suffer from immunodeficiency disease, and that the adoption of” Rilzbrotinip “embodies our common commitment to placing patients at the core of our efforts, and providing advanced therapeutic solutions that meet the most urgent medical needs.